분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2015-07-10 01:13:39 , Hit : 773
 Gene Therapy Allows Beethoven Mouse to Hear

GEN News HighlightsMore »
Jul 9, 2015


Scientists have made another step forward toward delivering on the massive potential of gene therapy to reverse the underlying mutations that are the basis for various genetic disorders. Specifically, researchers from the Boston Children’s Hospital and Harvard Medical School have been able to restore hearing in mice with a genetic form of deafness, using a gene therapy approach.

The investigators focused on a gene called transmembrane channel-like protein 1 (TMC1), which resides on the tip of hair cells within the cochlea. TMC1 forms a channel that allows calcium to enter the cell when moved by sound waves, inducing an electrical signal that is sent to the brain and interpreted as an auditory signal. The researchers chose TMC1, as it is a common cause of genetic deafness, accounting for close to 8% of cases.

Our gene therapy protocol is not yet ready for clinical trials—we need to tweak it a bit more—but in the not-too-distant future we think it could be developed for therapeutic use in humans," explained senior author Jeffrey Holt, Ph.D., associate professor of otolaryngology at Harvard Medical School.

The results from this study were published recently in Science Translational Medicine through an article entitled “Tmc gene therapy restores auditory function in deaf mice.”

Dr. Holt and his colleagues engineered an adeno-associated virus 1 (AAV1) to contain a functional copy of the TMC1 gene along with a promoter sequence, to make certain that the gene was turned on properly, and injected into the inner ear of two mouse strains. In one strain, the TMC1 gene was completely deleted and the other strain, the so-called Beethoven mice, contained single mutation within the TMC1 gene, rendering it ineffective. Both strains are good models for the dominant and recessive forms of TMC1 deafness within humans

After delivery of AAV1, the researchers tested the hearing of the mice by placing them into a “startle box”, where loud tones were administered and mice reactions are measured through a force plate on the floor beneath them. Remarkably, the scientists observed that both strains of mice were able to pick up the auditory signals.

Additionally, the researchers noticed that the gene therapy treated mice began to detect sounds around the 80-decibel range, which is not typical for TMC1 mutants. "Mice with TMC1 mutations will just sit there, but with gene therapy, they jump as high as a normal mouse," said Dr. Holt.

Ultimately, Dr Holt and his colleagues hope to partner with clinicians at Boston Children's department of otolaryngology and elsewhere to start clinical trials of TMC1 gene therapy within 5 to 10 years.

Current therapies for profound hearing loss like that caused by the recessive form of TMC1 are hearing aids, which often don't work very well, and cochlear implants," said Margaret Kenna, M.D., a specialist in genetic hearing loss at Boston Children's Hospital who is familiar with the current study. "Cochlear implants are great, but your own hearing is better in terms of range of frequencies, nuance for hearing voices, music and background noise, and figuring out which direction a sound is coming from. Anything that could stabilize or improve native hearing at an early age is really exciting and would give a huge boost to a child's ability to learn and use spoken language."

The investigators believe that other forms of genetic deafness may also be amenable to the same gene therapy strategy, as severe to profound hearing loss in both ears affects 1 to 3 per 1,000 live births.

"I can envision patients with deafness having their genome sequenced and a tailored, precision medicine treatment injected into their ears to restore hearing," Dr. Holt concluded.








1067   혈액 암과 면역세포의 DNA 편집의 관계  이성욱 2015/09/14 880
1066   아스피린이 암의 면역요법 효과 증대  이성욱 2015/09/08 770
1065   처음으로 밝혀진 수면부족과 감기 간의 관련성  이성욱 2015/09/03 806
1064   알츠하이머 질환에 대한 항체약물의 가능성  이성욱 2015/07/30 953
1063   DNA 앰블런스  이성욱 2015/07/30 898
1062   유전자 넉아웃을 보상하는 또 다른 유전자  이성욱 2015/07/30 1137
1061   FDA approves hepatitis C drugs from AbbVie, Bristol-Myers  이성욱 2015/07/28 828
1060   항-PD-1 항체에 저항성을 보이는 기작  이성욱 2015/07/28 994
1059   항체 함암제를 테스트할 수 있는 인간화 생쥐 모델  이성욱 2015/07/28 1247
1058   생명과학 연구에서 암컷쥐가 필요한 이유  이성욱 2015/07/23 907
1057   제 3 자의 혈액을 이용한 T 세포 면역치료  이성욱 2015/07/22 1000
  Gene Therapy Allows Beethoven Mouse to Hear  이성욱 2015/07/10 773
1055    기능 향상에 효과를 입증한 낭포성 섬유증 환자들에 대한 첫번째 유전자 요법  이성욱 2015/07/07 1227
1054   프리온 유사 단백질이 장기 기억을 유지시킨다고?  이성욱 2015/07/06 1260
1053   韓中 연구진, TALEN 기술로 초근육질 돼지 만들어  이성욱 2015/07/02 1113
1052   microRNA가 췌장암 치료제가 될 수 있을까  이성욱 2015/06/30 964
1051   T 세포 면역 치료를 향상시키는 유전자  이성욱 2015/06/29 1923
1050   A single gene turns colorectal cancer cells back into normal tissue in mice  이성욱 2015/06/23 876
1049   프리온 질환을 막는 유전자 돌연변이  이성욱 2015/06/15 902
1048   한국의 MERS가 글로벌 보건을 위협할 수 있을까?  이성욱 2015/06/09 858

[이전 10개] [1].. 11 [12][13][14][15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2020 Zeroboard / skin by ROBIN